Inflammatory bowel disease-associated thromboembolism: A systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis

Tabibian, James H.; Streiff, Michael B.

doi:10.1002/ibd.21307

Cited by 22 publications

(7 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…have been suggested as additional predisposing factors that increase the risks of venous thromboembolism (58,(58)(59)(60). Studies have shown that these interventions can precipitate a transient hyper-coagulative phase in the vascular system which might further increase the risks of venous thromboembolism in inflammatory bowel disease patients (61,62).…”

Section: Discussionmentioning

confidence: 99%

“…These inflammatory changes lead to the development of Virchow's triad (vascular injury, hemostasis, and hypercoagulation), ultimately resulting in increased incidence of venous thromboembolism ( 56 , 57 ). In the existing literature, even the therapeutic interventions (i.e., steroid therapy, abdominal surgery, central venous catheter) generally administered to manage inflammatory bowel disease have been suggested as additional predisposing factors that increase the risks of venous thromboembolism ( 58 , 58 – 60 ). Studies have shown that these interventions can precipitate a transient hyper-coagulative phase in the vascular system which might further increase the risks of venous thromboembolism in inflammatory bowel disease patients ( 61 , 62 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Zhang

Wang

2021

Front. Med.

View full text Add to dashboard Cite

Background: Patients suffering from chronic inflammatory disorders, such as inflammatory bowel disorder, are at higher risk of developing thromboembolism. The chronic inflammatory nature of inflammatory bowel disease has been identified as a predominant reason for a state of Virchow's triad (i.e., endothelial dysfunction, stasis, and general hypercoagulability), eventually leading to the onset of venous thromboembolism. Recent studies show that certain factors, such as demographics, medication history, and history of surgical intervention may increase thromboembolism risk in patients with inflammatory bowel disease. However, to date, no study has attempted to evaluate the effect of different risk factors associated with the development of venous thromboembolism in inflammatory bowel disease patients.Objective: To evaluate the risk factors that can influence the incidence of venous thromboembolism in patients with inflammatory bowel disease.Methods: Academic literature was systematically searched based on the PRISMA guidelines across five databases: Web of Science, EMBASE, CENTRAL, Scopus, and MEDLINE. A random-effect meta-analysis was conducted to evaluate the hazard ratio for the risk factors (i.e., aging, gender, steroid therapy, surgery, and ulcerative colitis) that can influence the incidence of venous thromboembolism in patients with inflammatory bowel disease.Results: From a total of 963 studies, 18 eligible studies with 1,062,985 (44.59 ± 10.18 years) patients suffering from inflammatory bowel disease were included in the review. A meta-analysis revealed a higher risk of aging (Hazard's ratio: 2.19), steroids (1.87), surgery (1.48), and ulcerative colitis (2.06) on venous thromboembolism in patients with inflammatory bowel disease. We also found that the female gender (0.92) did not increase the incidence of venous thromboembolism in inflammatory bowel disease patients.Conclusion: The study provides preliminary evidence regarding high risks associated with ulcerative colitis, steroid consumption, and aging for the development of venous thromboembolism in patients with inflammatory bowel disease. The findings from this study may contribute to developing awareness among clinicians, better risk stratification and prevention of venous thromboembolic complications in patients with inflammatory bowel disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Zhang

Wang

2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…However, early clinical trials using heparin as treatment for severe steroid‐refractory UC suggested anticoagulants are safe with respect to complications of bleeding . Furthermore, catheter‐directed thrombolysis has been used for IBD‐associated thromboembolism and appears to be well tolerated in terms of haemorrhagic complications . Current ECCO practice guidelines for the management of IBD advocate the use of antithrombotic prophylaxis in all hospitalised UC and CD patients .…”

Section: Discussionmentioning

confidence: 99%

Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease

Dwyer

Javed²,

Hair

et al. 2014

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…In addition to the primary gastrointestinal manifestations of IBD, a wide-range of extra-intestinal manifestations (EIMs) have also been reported[ 3 , 4 ]. One of the well-recognized EIMs of IBD is the increased risk of thromboembolic phenomena[ 5 - 7 ]. Several recent studies have demonstrated a two to four-fold increased risk of atherosclerotic cardiovascular disease (ASCVD) in patients with IBD as compared to the general population[ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation

Weissman

Sinh

Mehta

et al. 2020

WJGP

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) causes systemic vascular inflammation. The increased risk of venous as well as arterial thromboembolic phenomena in IBD is well established. More recently, a relationship between IBD and atherosclerotic cardiovascular disease (ASCVD) has been postulated. Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have well characterized cardiac pathologies and treatments that focus on prevention of disease associated ASCVD. The impact of chronic inflammation on ASCVD in IBD remains poorly characterized. This manuscript aims to review and summarize the current literature pertaining to IBD and ASCVD with respect to its pathophysiology and impact of medications in order to encourage further research that can improve understanding and help develop clinical recommendations for prevention and management of ASCVD in patients with IBD.

show abstract

Inflammatory bowel disease-associated thromboembolism: A systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis

Cited by 22 publications

References 49 publications

Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease

Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation

Contact Info

Product

Resources

About